Bloomberg

GSK Agrees to Buy Nuvalent for $10.6 Billion

Share

GSK agreed to buy Nuvalent in a deal valued at $10.6 billion, adding a biotech firm that's developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise. Sam Fazeli of Bloomberg Intelligence has more.

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.